

ASX Announcement

12 March 2026

Results of Extraordinary General Meeting

Sydney, Australia – 12 March 2026 OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), advises that all resolutions considered at the Extraordinary General Meeting held today were carried by poll.

In accordance with ASX Listing rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, details of the proxies received and votes cast in respect of each resolution are attached.

Ends.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Tim Luscombe Company Secretary E: tim.luscombe@bio101.com T: +61 429 707 079	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338
--	---	---

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>

OncoSil Medical Ltd
Extraordinary General Meeting
Thursday, 12 March 2026
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried	
1A. Approval of Issue of Tranche 2 Placement Shares	Ordinary	7,322,548 99.30%	28,700 0.39%	22,914 0.31%	15,433	7,345,462 99.61%	28,700 0.39%	15,433	Carried	N/A
1B. Approval of Issue of Placement Options (Tranche 1 and 2)	Ordinary	7,317,918 99.24%	31,535 0.43%	24,544 0.33%	15,598	7,342,462 99.57%	31,535 0.43%	15,598	Carried	N/A
2. Approval of Issue of Lead Manager Options	Ordinary	7,477,575 99.03%	43,625 0.58%	29,708 0.39%	26,523	7,507,283 99.42%	43,625 0.58%	26,523	Carried	N/A
3. Approval of Director Participation in Placement - Nigel Lange	Ordinary	7,474,692 99.04%	43,243 0.57%	29,708 0.39%	26,038	7,504,400 99.43%	43,243 0.57%	26,038	Carried	N/A
4. Approval of Director Participation in Placement - Thomas Duthy	Ordinary	7,437,375 99.02%	43,243 0.58%	29,708 0.40%	67,105	7,467,083 99.42%	43,243 0.58%	67,105	Carried	N/A
5. Approval of Director Participation in Placement – Lel Smits	Ordinary	7,461,489 98.81%	43,243 0.57%	46,661 0.62%	26,038	7,508,150 99.43%	43,243 0.57%	26,038	Carried	N/A
6. Ratification of Prior Issue of Placement Shares	Ordinary	7,311,877 99.16%	39,206 0.53%	22,914 0.31%	15,598	7,334,791 99.47%	39,206 0.53%	15,598	Carried	N/A
7. Approval of Issue of Remuneration Shares to Nigel Lange in Lieu of Salary	Ordinary	7,502,366 99.29%	31,346 0.41%	22,914 0.30%	17,055	7,525,280 99.59%	31,346 0.41%	17,055	Carried	N/A

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.